Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

36 “ 30 million tonnes of PVC were consumed worldwide in 2005.” Solvay Global Annual Report 2005 Vinyls (Polyvinyl Chlorides (PVC), performance compounds and Pipelife, a 50/50 joint venture with Wienerberger in pipes and fi ttings). 30 million tonnes of PVC were consumed worldwide in 2005, up 3% from 2004. China again stood out with growth of around 10%, consuming almost 7.5 million tonnes in 2005, more than the whole of Western Europe. PVC prices fl uctuated signifi cantly during 2005, refl ecting both the supply/demand balance and costs of raw materials and utilities. After peaking at the end of 2004, PVC prices reached a low in summer 2005 before beginning to recover signifi cantly from September onwards, owing to major production losses in the USA from Hurricanes Katrina and Rita. Vinyls margins, excellent during the fi rst quarter of 2005, deteriorated signifi cantly during the second quarter, recovering later from September onwards. Average results for Vinyls for the year as a whole remained at an excellent level, and above those of 2004. In a highly competitive European situation, SolVin (owned 75% by Solvay and 25% by BASF) used the reliability of its plants and its high degree of raw materials integration to maximize production. SolVin continued its quest for competitiveness by closing down its modestsized Ludwigshafen (Germany) unit at the end of 2005, and bringing on line new capacities at its Jemeppe (Belgium) and Rheinberg (Germany) sites. SolVin’s profi ts fully refl ect its excellent competitiveness. Eastern Europe also contributed very signifi cantly to demand for PVC made in Western Europe, with strongly rising imports of semi-fi nished products (profi les, fl oor covering, piping and fi ttings) and a shortage of PVC resins in the also fast-growing Russian market. The fi fth report of Vinyl 2010, the voluntary accord of the PVC industry in which Solvay plays an active part, was published in May 2005. It shows that the achievement of objectives for recycling levels is continuing to meet the plan. The VINYLOOP ® unit at Ferrara (Italy) continues to develop in terms of production levels, new technology and applications for recycled PVC, despite a European economic environment that remains unattractive for recycling projects. During 2005 SolVin continued its feasibility study for an integrated world-scale unit in Russia. Plastics Sector This would enable it to consolidate its leadership in Europe and to pursue its geographic diversifi cation towards Russia, where demand for PVC is rising sharply, and which offers competitive advantages in terms of raw materials. The feasibility study should reach the decision stage in 2006. In Mercosur, Solvay Indupa a listed Argentine company in which Solvay has a majority shareholding, also enjoyed very favourable conditions on the Argentine market. Demand on the Brazilian market, on the contrary, suffered from prohibitive interest rates, which placed a severe rein on construction investment. The excellent competitiveness and the good operating qualities of the Argentine and Brazilian installations are key factors which again generated an excellent result.
Plastics 37 Solvay Global Annual Report 2005
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19 and 20: Key fi gures [EUR million] Pharmace
Page 21 and 22: Cardiometabolic Cardiovascular dise
Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39: Innovation “Twin-Sheet Blow Mould
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?